Selvi Ersoy, Ph.D
Assistant Adjunct Professor
Dr. Ersoy has been an Investigator at the Lundquist Institute (TLI) and an Assistant Adjunct Professor at the David Geffen School of Medicine at UCLA since 2024. Dr. Ersoy earned her Ph.D. from the University of California Santa Barbara in 2017 in the department of Molecular, Cellular, and Developmental Biology in the laboratory of Dr. Michael Mahan. There, she studied the impacts of host-mimicking media on antimicrobial susceptibility profiles in various Gram-negative and Gram-Positive pathogens, including Salmonella, Escherichia coli, Streptococcus pneumonia, and methicillin-resistant Staphylococcus aureus (MRSA).
In 2017, Dr. Ersoy joined the lab of Dr. Arnold Bayer at TLI for her post-doctoral training. Her research focused on the ability of HCO3, an abundant ion in mammalian tissues and blood, to stimulate MRSA sensitivity to β-lactam antibiotics both in vitro and in vivo. Dr. Ersoy has continued to investigate the scope, mechanisms, and translatability of this phenomenon in her current roles as Investigator and Faculty at TLI and the David Geffen School of Medicine. The primary goal of her research is to identify novel anti-MRSA therapeutic strategies for clinical practice.
Areas of Expertise
- Novel mechanisms of antimicrobial susceptibility
- Bacterial genetics and genetic manipulation techniques
- Rabbit model of MRSA experimental infective endocarditis
Education
- B.S. Genetics, University of California Irvine, 2006 – 2010
- Ph.D. and M.A. Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, 2010 – 2017
- Post-doctoral Fellowship, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, 2017 – 2022
Publications
Notable recent publications:
Ersoy, SC, Proctor, RA, Rose, RE, Abdelhady, W, Fan, SH, Madrigal, SL, Elsayed, AM, Chambers, HF, Sobral, RG, Bayer, AS. 2024. Sensitizing methicillin-resistant Staphyloccocus aureus (MRSA) to cefuroxime: the synergic effect of bicarbonate and the wall teichoic acid inhibitor ticlopidine. Antimicrob Agents Chemother 68:e01627-23.
Ersoy SC, Gonçalves B, Cavaco G, Manna AC, Sobral RG, Nast CC, Proctor RA, Chambers HF, Cheung A, Bayer AS. 2022. Influence of sodium bicarbonate on wall teichoic acid synthesis and β-lactam sensitization in NaHCO3-responsive and nonresponsive methicillin-resistant Staphylococcus aureus. Microbiol Spectr 10:e0342222.
Ersoy SC, Chambers HF, Proctor RA, Rosato AE, Mishra NN, Xiong YQ, Bayer AS. 2021. Impact of bicarbonate on PBP2a production, maturation, and functionality in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 65:e02621-20.
Ersoy SC, Abdelhady W, Li L, Chambers HF, Xiong YQ, Bayer AS. 2019. Bicarbonate resensitization of methicillin-resistant Staphylococcus aureus to β-Lactam antibiotics. Antimicrob Agents Chemother 63:e00496-19.
A list of publications can be found here
© 2024 Lundquist. All rights reserved